Shell Asset Management’s Heron Therapeutics HRTX Stock Holding History

Shell Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8,523	Closed	-$180K	–	1468
2020 Q4	$180K	Hold	8,523	–	–	﹤0.01%	1149
2020 Q3	$126K	Hold	8,523	–	–	﹤0.01%	1136
2020 Q2	$125K	Sell	8,523 -70	-0.8%	-$1.15K	﹤0.01%	1121
2020 Q1	$101K	Sell	8,593 -132	-2%	-$2.48K	﹤0.01%	1117
2019 Q4	$205K	Sell	8,725 -262	-3%	-$5.8K	﹤0.01%	1127
2019 Q3	$166K	Sell	8,987 -77	-0.8%	-$1.42K	﹤0.01%	1154
2019 Q2	$169K	Sell	9,064 -207	-2%	-$4.13K	﹤0.01%	1139
2019 Q1	$227K	Hold	9,271	–	–	0.01%	1086
2018 Q4	$240K	Sell	9,271 -800	-8%	-$22K	0.01%	1012
2018 Q3	$319K	Buy	+10,071	New	+$375K	0.01%	1056

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Shell Asset Management's HRTX Position: Q1 2021 in Review

Shell Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 8,523 shares — an estimated $180K sold.

Shell Asset Management first reported a position in HRTX in Q3 2018 and held it in 10 quarters. The position peaked at $319K in Q3 2018. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

Shell Asset Management reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
Shell Asset Management sold 8,523 Heron Therapeutics shares in Q1 2021, an estimated $180K.
Shell Asset Management first reported a position in Heron Therapeutics in Q3 2018 and held it in 10 quarters.
Shell Asset Management's Heron Therapeutics position peaked at $319K in Q3 2018.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Shell Asset Management's 13F filing for Q1 2021, filed 10 May 2021.